Nanorelief gel: an advanced celecoxib nanoemulgel for effective pain and inflammation relief

Celecoxib (CXB) is a medication for the treatment of relieving pain and reducing inflammation in osteoarthritis and rheumatoid arthritis. It has low bioavailability when administered orally due to its lipophilic nature and low water solubility. Transdermal administration can allow targeted drug delivery without first-pass metabolism. However, it is difficult to get through the outermost layer of the skin due to the nature of the stratum corneum. To solve this issue, nanoemulsion (NE) serves as a vehicle for the delivery of various active pharmaceutical ingredients and has attracted great attention in the drug delivery field. One of our approaches is to modify NE into a new dosage form, which is nanoemulgel (NEG) for improved skin permeability. NanoRelief Gel is a topical gel that contains CXB as the active component. The gel's particle size of 149.07±1.42 nm demonstrates great permeability and therapeutic effects, with a narrow size distribution of 0.21±0.01 and good stability with the zeta potential value of -33.07±2.87 mV. NanoRelief gel provides effective alternative to traditional oral pain relief medications and can be site-specific, further enhancing its effectiveness. It has strong commercial potential value for arthritis patients due to its safety and effectiveness.